Phase II Study of High-Dose Lovastatin in Patients with Advanced Gastric Adenocarcinoma

Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park K, Kang YK, Shin DB, Kim HT, Kim HJ, Kang WK, Suh CI, Bang YJ: A phase III randomized study of 5–fluorouracil and cisplatin versus 5–fluorouracil, doxorubicin, and mitomycin C versus 5–fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71: 3813–3818, 1993

Kelsen D: The use of chemotherapy in the treatment of advanced gastric and pancreas cancer. Seminar Oncol 21: 58–66, 1994

Alexander HR, Kelsen DP, Tepper JE: Cancer of the stomach. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer. Lippincott-Raven Publ Corp, New York, 1997, pp 1021–1053

Keyomarsi K, Sandoval L, Band V, Pardee AB: Synchronization of tumor and normal cells from GI to multiple cell cycles by lovastatin. Cancer Res 51: 3602–3609, 1991

Prasanna P, Thibault A, Liu L, Samid D: Lipid metabolism as target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. J Neurochem 66: 710–716, 1996

Jakobisiak M, Bruno S, Skierski S, Zbigniew D: Cell cyclespecific effects of lovastatin. Proc Natl Acad Sci USA 88: 3628–3632, 1991

DeClue JF, Vass WC, Papageorge AG, Lowy DR, Willumsen BM: Inhibition of cell growth by lovastatin is independent of ras function. Cancer Res 51: 712–717, 1991

Maltese WA, Defendini R, Green RA, Sheridan KM, Donley DK: Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3–hydroxy-3–methylglutaryl-coenzyme A reductase. J Clin Invest. 76: 1745–1754, 1985

Sebti SM, Tkalcevic GT, Jani JP. Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice. Cancer communications. 3: 141–147, 1991

Thibault A, Samid D, Tompkins AC, Figg VVD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, Reed E, Myers CE: Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2: 483–491, 1996 Address for offprints: Won Ki Kang, MD, PhD, Division of Hematology/ Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, 50 Ilwon-Dong, Kangnam-Ku, Seoul 135–710, Korea.